<DOC>
	<DOC>NCT00461955</DOC>
	<brief_summary>Hematopoietic reconstitution defined by a neutrophils number &gt; 500/mm3 at day 7 after injection of ex vivo amplified graft and by a platelets number &gt; 20000/mm3, at day 15 after the injection of ex vivo amplified graft, without transfusion.</brief_summary>
	<brief_title>Injection of ex Vivo Amplified G-CSF Mobilised Autologous Peripheral Blood Stem Cell Transplantation</brief_title>
	<detailed_description>To check that injection of autologous peripheral blood stem cell CD34(+) "amplified ex vivo in the presence of SCF, G-CSF and TPO in HP01 Maco pharma medium culture. ": Allows to obtain a hematopoietic reconstitution: 1. Rapid : 7 days or less after the injection, regarding neutrophils and 15 days or less regarding platelets 2. Complete: numbers neutrophils and platelets respectively higher than 500/mm3 and 20000/mm3 within the times mentioned 3. Stable: no secondary neutropenia or thrombocytopenia during the year following the injection, in the absence of recurence of the myeloma.</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>Patient between 18 and 65 years of age Diagnosis of Multiple Myeloma, requiring a treatment, including high dose Melphalan whith autologous peripheral blood stem cell transplantation Performance status: &lt; 2 (Karnofsky &gt; 70%) Anticipated survival &gt; 3 month Collection of a minimum of 10x106 cells (CD34+)/Kg of autologous GCSF mobilised peripheral blood stem cells in 2 to 3 pheresis. Signed and dated informed consent Multiple Myeloma not requiring a treatment Another cancer in the 5 years preceding the diagnosis or evolutive psychiatric affection Positive serology for HIV, hepatitis C or hepatitis B Hepato cellular insufficiency Severe renal insufficiency defined by a creatine clearance &lt; 30 ml/mn Women pregnant or nursing, or effective absence of contraception Antecedent of serious cardiac disease in the last 6 months. Allergy known to the products derived from Escherichia Coli</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Symptomatic Multiple Myeloma</keyword>
	<keyword>first line treatment</keyword>
	<keyword>first autologous Stem Cell Transplantation</keyword>
	<keyword>ex vivo amplified autologous peripheral blood stem cells</keyword>
</DOC>